Predictors of Cladribine Effectiveness and Safety in Multiple Sclerosis: A Real-World, Multicenter, 2-Year Follow-Up Study

Jacobs BM(2018)Cladribine: mechanisms and mysteries in multiple sclerosis J Neurol Neurosurg Psychiatry 89 1266-1271

Ammoscato F(2018)Safety and efficacy of cladribine tablets in patients with relapsing–remitting multiple sclerosis: results from the randomized extension trial of the CLARITY study Mult Scler J 24 1594-1604

Giovannoni G(2022)Analysis of frequency and severity of relapses in multiple sclerosis patients treated with cladribine tablets or placebo: the CLARITY and CLARITY Extension studies Mult Scler J 28 111-120

Baker D(2021)Durability of no evidence of disease activity-3 (NEDA-3) in patients receiving cladribine tablets: the CLARITY extension study Mult Scler J 38 4975-4985

Schmierer K(2021)Long-term disease stability assessed by the expanded disability status scale in patients treated with cladribine tablets 3.5 mg/kg for relapsing multiple sclerosis: an exploratory post hoc analysis of the CLARITY and CLARITY extension studies Adv Ther 13 1756286420922685-54

Giovannoni G(2020)Long-term effectiveness in patients previously treated with cladribine tablets: a real-world analysis of the Italian multiple sclerosis registry (CLARINET-MS) Ther Adv Neurol Disord 11 489-827

Soelberg Sorensen P(2020)Single-center 8-years clinical follow-up of cladribine-treated patients from phase 2 and 3 trials Front Neurol 1 49-464

Cook S(2012)Cladribine tablets for relapsing-remitting multiple sclerosis: Efficacy across patient subgroups from the phase III CLARITY study Mult Scler Relat Disord 25 819-1174

Rammohan K(2019)Efficacy of Cladribine Tablets in high disease activity subgroups of patients with relapsing multiple sclerosis: a post hoc analysis of the CLARITY study Mult Scler 37 459-268

Rieckmann P(2021)Efficacy of cladribine tablets in high disease activity patients with relapsing multiple sclerosis: post hoc analysis of subgroups with and without prior disease-modifying drug treatment Curr Med Res Opin 18 1166-333

Jacobs BM(2018)Cladribine: mechanisms and mysteries in multiple sclerosis J Neurol Neurosurg Psychiatry 89 1266-1271

Ammoscato F(2018)Safety and efficacy of cladribine tablets in patients with relapsing–remitting multiple sclerosis: results from the randomized extension trial of the CLARITY study Mult Scler J 24 1594-1604

Giovannoni G(2022)Analysis of frequency and severity of relapses in multiple sclerosis patients treated with cladribine tablets or placebo: the CLARITY and CLARITY Extension studies Mult Scler J 28 111-120

Baker D(2021)Durability of no evidence of disease activity-3 (NEDA-3) in patients receiving cladribine tablets: the CLARITY extension study Mult Scler J 38 4975-4985

Schmierer K(2021)Long-term disease stability assessed by the expanded disability status scale in patients treated with cladribine tablets 3.5 mg/kg for relapsing multiple sclerosis: an exploratory post hoc analysis of the CLARITY and CLARITY extension studies Adv Ther 13 1756286420922685-54

Giovannoni G(2020)Long-term effectiveness in patients previously treated with cladribine tablets: a real-world analysis of the Italian multiple sclerosis registry (CLARINET-MS) Ther Adv Neurol Disord 11 489-827

Soelberg Sorensen P(2020)Single-center 8-years clinical follow-up of cladribine-treated patients from phase 2 and 3 trials Front Neurol 1 49-464

Cook S(2012)Cladribine tablets for relapsing-remitting multiple sclerosis: Efficacy across patient subgroups from the phase III CLARITY study Mult Scler Relat Disord 25 819-1174

Rammohan K(2019)Efficacy of Cladribine Tablets in high disease activity subgroups of patients with relapsing multiple sclerosis: a post hoc analysis of the CLARITY study Mult Scler 37 459-268

Rieckmann P(2021)Efficacy of cladribine tablets in high disease activity patients with relapsing multiple sclerosis: post hoc analysis of subgroups with and without prior disease-modifying drug treatment Curr Med Res Opin 18 1166-333